

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 September 2024 (06.09.2024)



(10) International Publication Number
WO 2024/180201 A1

(51) International Patent Classification:

A61K 31/42 (2006.01) *A61K 45/06* (2006.01)
A61K 31/519 (2006.01) *A61K 9/20* (2006.01)
A61K 31/7125 (2006.01) *A61P 21/00* (2006.01)
A61K 31/501 (2006.01)

(21) International Application Number:

PCT/EP2024/055308

(22) International Filing Date:

01 March 2024 (01.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/488,055	02 March 2023 (02.03.2023)	US
23162356.2	16 March 2023 (16.03.2023)	EP
23208554.8	08 November 2023 (08.11.2023)	EP

(71) Applicant: **NMD PHARMA A/S** [DK/DK]; Palle Juul-Jensens Boulevard 82, 8200 Aarhus N (DK).

(72) Inventors: **BASTIAS, Jorge Armando Quiroz**; C/O NMD Pharma A/S, Palle Juul-Jensens Boulevard 82, 8200 Aarhus N (DK). **PEDERSEN, Thomas Holm**; C/O NMD Pharma A/S, Palle Juul-Jensens Boulevard 82, 8200 Aarhus N (DK). **GRØNNEBÆK, Thomas Skjærlund**; C/O NMD Pharma A/S, Palle Juul-Jensens Boulevard 82, 8200 Aarhus N (DK). **CHIN, Eva Rose**; 75750 Heritage Dr. W, Palm Desert, California CA 92211 (US). **BOLD, Jane Mary**; Dairy Barn, Honor End Lane, Great Missenden Buckinghamshire HP16 9QZ (GB). **SKOV, Martin Brandhøj**; C/O NMD Pharma A/S, Palle Juul-Jensens Boulevard 82, 8200 Aarhus N (DK).

(74) Agent: **HØIBERG P/S**; Adelgade 12, 1304 Copenhagen K (DK).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(54) Title: COMPOSITIONS AND METHODS FOR TREATING SPINAL MUSCULAR ATROPHY

(57) Abstract: Disclosed herein are methods of treatment for spinal muscular atrophy (SMA) that involve administering (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid, or a pharmaceutical composition thereof, to a patient suffering from symptoms of SMA. Pharmaceutical compositions and kits-to-parts including (2S)-2-[4-bromo-2-(1,2-oxazol-5-yl)phenoxy]propanoic acid are also disclosed.

WO 2024/180201 A1